Srdan Verstovsek, MD, The University of Texas MD Anderson Cancer, Houston, TX, outlines current and emerging treatments for patients with polycythemia vera (PV). Today, most patients with PV are treated with phlebotomy, aspirin, and cytoreductive therapies, of which the most commonly used is hydroxyurea and more recently, ropeginterferon alfa-2b. Dr Verstovsek explains that adding rusfertide to cytoreductive therapy could eliminate the need for phlebotomy and normalize hematocrit levels, therefore reducing the risk of death. This strategy is going to be evaluated in a Phase III trial. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

свернуть